Rational design, ligand engineering, and formulation optimization for tissue- and cell-directed lipid nanoparticle systems.
Targeted LNP development has become a central focus in nucleic acid and precision nanomedicine programs because conventional lipid nanoparticles often achieve efficient payload protection but insufficient delivery selectivity outside preferred biological uptake pathways. Successful targeted systems require more than adding a ligand to the particle surface. They depend on coordinated control of ionizable lipid composition, helper lipid balance, PEG-lipid behavior, payload compatibility, ligand presentation, colloidal stability, and downstream functional validation. BOC Sciences provides targeted LNP development services designed to help researchers build, refine, and evaluate actively targeted lipid nanoparticle platforms for mRNA, siRNA, pDNA, oligonucleotides, proteins, peptides, and selected small molecules. Our workflow integrates formulation design, targeting ligand incorporation, physicochemical characterization, and performance-oriented screening to support efficient progression from concept to optimized candidate.
Targeted Lipid Nanoparticle DevelopmentWe offer a modular service framework for the development of targeted lipid nanoparticles, covering formulation architecture, ligand-functionalized surface engineering, screening design, and application-specific optimization. Our services are tailored for discovery teams seeking better delivery precision, stronger cell uptake, and more reliable translation of LNP performance across in vitro and in vivo research settings.
We begin with the intended tissue, cell population, payload modality, and administration route to define an LNP design space that aligns formulation variables with targeting objectives.
We build the non-targeted formulation backbone before or alongside surface targeting design, ensuring the carrier itself provides strong encapsulation, stability, and delivery competence.
We support active targeting strategies using ligand formats selected for receptor accessibility, conjugation feasibility, and compatibility with LNP colloidal behavior.
Targeting claims require comparative evidence. We design screening workflows to distinguish true receptor-mediated enhancement from nonspecific uptake.
We characterize the properties most likely to change during targeted LNP engineering and most likely to affect biological behavior.
We use stepwise optimization to improve selectivity and potency while maintaining manufacturable LNP properties.
Effective targeted lipid nanoparticle design requires control over both the delivery core and the targeting shell. We combine formulation knowledge with application-specific engineering strategies to improve the probability of selective and productive delivery.
Advance beyond generic LNP formulations with a development workflow focused on ligand functionality, tissue selectivity, and robust formulation behavior.
Our targeted LNP development services are suitable for diverse payload classes and research objectives. We adapt formulation architecture and surface engineering strategies to the intended delivery context rather than applying a one-size-fits-all workflow.
| Development Category | Targeted LNP Scope |
|---|---|
| Targeted LNPs for mRNA Delivery | Development of ligand-functionalized mRNA-loaded systems for cell-selective protein expression research, uptake optimization, and extrahepatic delivery exploration. |
| Targeted LNPs for siRNA Delivery | Formulation and screening of receptor-directed siRNA LNPs with emphasis on selective internalization, intracellular release, and gene-silencing-oriented delivery design. |
| Gene Delivery-Oriented Targeted LNP Development | Engineering of targeted LNP systems for plasmid, editing-related, or other nucleic acid cargoes requiring cell-specific access and productive intracellular trafficking. |
| LNP Formulation Optimization | Establishment of the core formulation backbone prior to or during surface targeting modification, including lipid ratio tuning and payload compatibility studies. |
| Encapsulation-Focused Development | Optimization of loading efficiency and formulation integrity for targeted systems where ligand engineering may alter assembly or payload retention. |
| Characterization of Targeted LNP Attributes | Assessment of size, PDI, zeta potential, morphology, ligand-related surface effects, and other physicochemical parameters critical to targeted performance. |
| Targeted LNP Stability Evaluation | Investigation of storage and dispersion stability after ligand incorporation, with attention to aggregation, fusion, and payload leakage risk. |
| Scale-Conscious LNP Process Development | Refinement of targeted LNP preparation workflows for reproducibility, process continuity, and smoother transition to broader production-oriented studies. |
Our targeted LNP development services are designed to support organ- and tissue-oriented delivery strategies by combining formulation optimization, ligand engineering, and application-specific screening.
✔ Liver-Targeted LNP Delivery
We support the development of targeted LNP systems for hepatocytes, liver sinusoidal endothelial cells, Kupffer cells, and other liver-associated cell populations. These programs may involve tuning lipid composition, surface ligands, and particle properties to improve selective hepatic uptake and functional intracellular delivery.
✔ Lung-Targeted LNP Delivery
Our services can support LNP development strategies for pulmonary delivery research, including approaches aimed at airway epithelial cells, alveolar regions, and lung-associated immune cells. We optimize formulation behavior and targeting design to help improve localization, uptake, and delivery efficiency in respiratory applications.
✔ Tumor-Targeted LNP Delivery
We develop targeted LNP systems for tumor-focused delivery studies by integrating receptor-oriented ligand strategies, payload-compatible formulation design, and comparative screening in cancer-relevant models. This supports improved delivery selectivity toward tumor cells or components of the tumor microenvironment.
✔ Spleen- and Immune Tissue-Targeted Delivery
We support LNP engineering for delivery to immune-related tissues and cell populations, including splenic and antigen-presenting cell targets. Our development workflows can be adapted for immunology-focused research requiring selective engagement of macrophages, dendritic cells, or lymphoid tissue-associated cells.
✔ Brain-Related and CNS-Oriented Delivery Research
For programs exploring delivery toward brain-associated or central nervous system-relevant targets, we provide targeted LNP development strategies focused on particle design, ligand selection, and biological screening logic. These efforts are tailored to help evaluate delivery opportunities in challenging tissue access scenarios.
✔ Muscle and Other Extrahepatic Tissue Delivery
We also support targeted LNP development for muscle and other extrahepatic tissues where selective delivery remains technically demanding. By refining ligand display, lipid composition, and formulation properties, we help clients investigate delivery strategies for tissue-specific uptake and improved payload activity beyond conventional distribution profiles.
We assess payload type, target cell or tissue, ligand options, formulation constraints, and intended study objectives to define a practical targeted LNP development plan.
We develop the LNP core system and integrate selected targeting elements through appropriate insertion or conjugation strategies while maintaining particle quality.
Targeted and control formulations are characterized and evaluated through physicochemical and functional studies to identify specificity, uptake, and delivery performance trends.
Based on screening outcomes, we refine composition and surface design variables and provide a structured report to support informed advancement of lead targeted LNP candidates.
Client Need: A client aimed to develop a targeted LNP formulation for siRNA delivery to liver-associated cells with improved cellular selectivity and stronger intracellular gene silencing performance than a conventional non-targeted system.
Project Challenge: The initial formulation achieved acceptable encapsulation efficiency, but its delivery profile remained too broad, and ligand introduction caused instability in particle size distribution. In addition, stronger cellular association did not consistently translate into improved functional payload activity.
Our Solution: BOC Sciences established a stepwise targeted LNP development workflow beginning with optimization of the core lipid composition to maintain a robust formulation backbone. We then evaluated ligand incorporation strategies, linker architecture, and ligand density to improve surface accessibility without compromising colloidal stability. Through comparative screening against non-targeted controls and multiple formulation variants, we correlated particle properties, uptake behavior, and siRNA functional performance to identify the most effective balance between selective targeting and intracellular delivery efficiency.
Result: The optimized targeted LNP candidate showed improved delivery preference toward the intended liver-associated cell model, better formulation uniformity, and stronger gene silencing activity relative to the starting prototype, providing a more credible lead system for continued development.
Client Need: A research team requested support in developing a targeted LNP platform for mRNA delivery to pulmonary cell populations, with the goal of improving tissue-oriented delivery performance and reducing nonspecific uptake outside the intended lung-related application setting.
Project Challenge: The project faced multiple formulation barriers, including reduced particle stability after ligand modification, inconsistent mRNA expression across screening models, and uncertainty regarding whether limited performance arose from insufficient targeting, inefficient internalization, or suboptimal intracellular delivery after uptake.
Our Solution: Our team redesigned the formulation by jointly optimizing ionizable lipid composition, helper lipid ratio, PEG-lipid content, and ligand presentation strategy. We developed a comparative screening framework to distinguish receptor-related targeting effects from nonspecific particle association and evaluated how surface engineering influenced both physicochemical quality and mRNA expression outcomes. This iterative approach enabled us to refine the targeted LNP architecture around the real delivery bottleneck rather than relying on ligand addition alone.
Result: The final formulation demonstrated improved particle consistency, clearer targeting-associated delivery behavior in pulmonary-relevant models, and enhanced mRNA functional readout compared with the original design, supporting further advancement of the targeted LNP concept.
Integrated Design LogicWe approach targeted LNP development as a combined formulation and biointerface problem, not merely a ligand conjugation task.
Payload VersatilityOur workflows support multiple cargo classes and can be adapted to discovery-stage and optimization-stage targeted LNP programs.
Surface Engineering ExpertiseWe evaluate ligand type, linker logic, density, and presentation mode to improve the probability of functional targeting.
Characterization-Oriented DevelopmentTargeted formulations are supported by structured physicochemical analysis to reveal how surface modifications affect overall LNP quality.
Optimization for Real Research QuestionsWe focus on the practical issues researchers face, including extrahepatic delivery difficulty, ligand masking, and inconsistent performance across models.
The challenge of targeted LNPs is not simply “attaching a ligand to the particle surface,” but rather balancing receptor recognition, surface ligand accessibility, particle stability, biodistribution, cellular uptake, and post-endocytic release at the same time. Recent studies broadly indicate that, for targeted LNPs to truly outperform conventional LNPs, developers must systematically optimize ionizable lipids, helper lipids, PEG-lipids, ligand density, and intracellular delivery processes, instead of optimizing only a single parameter. For drug development clients, this means that targeted LNP projects require a more integrated formulation development and validation strategy.
The choice of targeting ligand usually depends on receptor expression on the surface of the target organ or cell, ligand binding specificity, conjugation feasibility, and whether the ligand retains its function after being displayed on the particle. Higher affinity is not always better, because excessively high surface modification density may compromise PEG shielding, particle stability, and in vivo behavior. In targeted LNP development, BOC Sciences places greater emphasis on comprehensively evaluating ligand type, linkage strategy, and display density in combination with target cell characteristics, administration scenario, and cargo type, so as to improve actual delivery value rather than merely pursuing surface modification itself.
Not necessarily. Current literature generally suggests that LNPs naturally tend to accumulate in the liver, while efficient delivery to the lung, spleen, tumors, immune cells, or other extrahepatic tissues usually requires simultaneous adjustment of both lipid composition and surface engineering strategies. Recent studies have shown that, by modifying ionizable lipid and helper lipid structures and optimizing surface modifications, delivery preference can be shifted from the liver toward extrahepatic tissues such as the lung and pancreas. However, this remains highly dependent on the specific formulation system and experimental model. For clients, extrahepatic delivery is better suited to an iterative screening-based development pathway.
Successful targeting cannot be judged solely by enhanced cell binding or uptake. It must also be assessed by whether, compared with a non-targeted control, it truly improves functional delivery outcomes in the target cells. Recent reviews and methodological papers particularly emphasize that LNP distribution, cargo distribution, and the final expression or silencing outcome should all be tracked simultaneously, because “entering the cell” does not necessarily mean “successful release and function.” In project design, BOC Sciences recommends combining physicochemical characterization, cellular uptake, tissue distribution, and functional readouts to avoid mistaking a single indicator for true targeting capability.
The most common problems are usually not whether the ligand “has been attached,” but whether the ligand is masked by the protein corona or PEG layer, whether surface modification makes the particle unstable, whether endosomal escape is insufficient after cellular entry, or whether in vivo distribution is still dominated by the natural liver tropism of LNPs. Recent studies continue to point out that endosomal escape remains a key limiting factor in nucleic acid LNP delivery, while protein adsorption in biological fluids can also reshape the particle’s surface identity and affect targeting performance. Therefore, successful targeted LNP development must place ligand engineering, formulation optimization, and delivery mechanism analysis on equal footing.
